Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)

Carlos Tornero, Ernesto Pastor, María del Mar Garzando, Jorge Orduña, MJ Forner, Irene Bocigas, David L. Cedeño, Ricardo Vallejo, Peter Staats, View ORCID ProfileEric J. Liebler
doi: https://doi.org/10.1101/2021.09.24.21264045
Carlos Tornero
1Hospital Clínico Universitario de Valencia, Anesthesia, Critical Care and Pain Management Unit, Valencia, Spain
2Cátedra Dolor, UFV-Fundación Vithas, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernesto Pastor
1Hospital Clínico Universitario de Valencia, Anesthesia, Critical Care and Pain Management Unit, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María del Mar Garzando
1Hospital Clínico Universitario de Valencia, Anesthesia, Critical Care and Pain Management Unit, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Orduña
1Hospital Clínico Universitario de Valencia, Anesthesia, Critical Care and Pain Management Unit, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MJ Forner
3Hospital Clínico Universitario de Valencia, Internal Medicine Department, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Bocigas
4Hospital Clínico Universitario de Valencia, Pulmonary Department, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Cedeño
5Department of Basic Science, Millennium Pain Center, Bloomington, IL, USA
6Department of Psychology, Illinois Wesleyan University, Bloomington, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Vallejo
5Department of Basic Science, Millennium Pain Center, Bloomington, IL, USA
6Department of Psychology, Illinois Wesleyan University, Bloomington, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Staats
7electroCore, Inc., Rockaway, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: peter.staats@electrocore.com
Eric J. Liebler
7electroCore, Inc., Rockaway, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric J. Liebler
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Severe coronavirus disease 2019 (COVID-19) is characterized, in part, by an excessive inflammatory response. Evidence from animal and human studies suggests that vagus nerve stimulation can lead to reduced levels of various pro-inflammatory cytokines. We conducted a prospective randomized controlled study (SAVIOR-I) to assess the feasibility, efficacy, and safety of non-invasive vagus nerve stimulation (nVNS) for the treatment of respiratory symptoms and inflammatory markers among patients who were hospitalized for COVID-19 (ClinicalTrials.gov identifier: NCT04368156).

Methods Participants were randomly assigned in a 1:1 allocation to receive either the standard of care (SoC) alone or nVNS therapy plus the SoC. The nVNS group received 2 consecutive 2-minute doses of nVNS 3 times daily as prophylaxis. Efficacy and safety were evaluated via the incidence of specific clinical events, inflammatory biomarker levels, and the occurrence of adverse events.

Results Of the 110 participants who were enrolled and randomly assigned, 97 (nVNS, n=47; SoC, n=50) had sufficient available data and comprised the evaluable population. C-reactive protein (CRP) levels decreased from baseline to a significantly greater degree in the nVNS group than in the SoC group at day 5 and overall (ie, all postbaseline data points collected through day 5, combined). Procalcitonin level also showed significantly greater decreases from baseline to day 5 in the nVNS group than in the SoC group. D-dimer levels were decreased from baseline for the nVNS group and increased from baseline for the SoC group at day 5 and overall, although the difference between the treatment groups did not reach statistical significance. No significant treatment differences were seen for clinical respiratory outcomes or any of the other biochemical markers evaluated. No serious nVNS-related adverse events occurred during the study.

Conclusions nVNS therapy led to significant reductions in levels of inflammatory markers, specifically CRP and procalcitonin. Because nVNS has multiple mechanisms of action that may be relevant to COVID-19, additional research into its potential to be used earlier in the course of COVID-19 and possibly mitigate some of the symptoms associated with post-acute COVID-19 syndrome is warranted.

Competing Interest Statement

CT has nothing to disclose. EP has nothing to disclose. MdMG has nothing to disclose. JO has nothing to disclose. MJF has nothing to disclose. IB has nothing to disclose. DLC has served as a consultant and advisory board member for Medtronic, Inc. RV is Director of Research for the National Spine and Pain Centers, a consultant and advisory board member for Medtronic, Inc., and Chief Executive Officer for SGX Medical, LLC. PS is an employee and was cofounder of electroCore, Inc., and receives stock ownership. EJL is an employee of electroCore, Inc., and receives stock ownership.

Clinical Trial

NCT04368156

Funding Statement

electroCore, Inc. (Rockaway, NJ, USA) developed the gammaCore Sapphire device and provided devices at no cost for use in this study. Statistical analysis for the study conducted by North American Science Associates Inc. (Minneapolis, MN, USA) and editorial support from MedLogix Communications, LLC (Itasca, IL, USA) were funded by electroCore, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Ethics and Clinical Research Committee of INCLIVA, Valencia, Spain [https://www.incliva.es]. INCLIVA is accredited as a Health Research Institute by the Carlos III Health institute, and is affiliated with The Valencia University Clinical Hospital. The study was conducted in accordance with the Declaration of Helsinki and requirements of clinical trials registration (ClinicalTrials.gov identifier NCT04368156). Written informed consent from patients was required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Study funding electroCore, Inc. (Rockaway, NJ, USA) developed the gammaCore Sapphire™ device and provided devices at no cost for use in this study. Statistical analysis for the study conducted by North American Science Associates Inc. (Minneapolis, MN, USA) and editorial support from MedLogix Communications, LLC (Itasca, IL, USA) were funded by electroCore, Inc.

  • Author disclosures CT has nothing to disclose.

    EP has nothing to disclose.

    MdMG has nothing to disclose.

    JO has nothing to disclose.

    MJF has nothing to disclose.

    IB has nothing to disclose.

    DLC has served as a consultant and advisory board member for Medtronic, Inc.

    RV is Director of Research for the National Spine and Pain Centers, a consultant and advisory board member for Medtronic, Inc., and Chief Executive Officer for SGX Medical, LLC.

    PS is an employee and was cofounder of electroCore, Inc., and receives stock ownership.

    EJL is an employee of electroCore, Inc., and receives stock ownership.

  • Data availability statement: Data from the SAVIOR I study will be publicly available at ClinicalTrials.gov with the identifier NCT04368156. Individual participant data will not be shared.

Data Availability

Data from the SAVIOR I study will be publicly available at ClinicalTrials.gov with the identifier NCT04368156. Individual participant data will not be shared.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
Carlos Tornero, Ernesto Pastor, María del Mar Garzando, Jorge Orduña, MJ Forner, Irene Bocigas, David L. Cedeño, Ricardo Vallejo, Peter Staats, Eric J. Liebler
medRxiv 2021.09.24.21264045; doi: https://doi.org/10.1101/2021.09.24.21264045
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
Carlos Tornero, Ernesto Pastor, María del Mar Garzando, Jorge Orduña, MJ Forner, Irene Bocigas, David L. Cedeño, Ricardo Vallejo, Peter Staats, Eric J. Liebler
medRxiv 2021.09.24.21264045; doi: https://doi.org/10.1101/2021.09.24.21264045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1262)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10055)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)